Costs of Treating Colorectal Cancer Detected by Screening
Author Information
Author(s): D.K. Whynes, A.R. Walker, J.O. Chamberlain, J.D. Hardcastle
Primary Institution: University Hospital, Nottingham
Hypothesis
Screening will result in more cancers being detected at the earlier stages of the disease, leading to lower average treatment costs.
Conclusion
The study found that early detection of colorectal cancer through screening does not significantly reduce hospital treatment costs compared to cancers detected symptomatically.
Supporting Evidence
- Mean treatment costs for screen-detected cancers were ?3,179, while for the control group it was ?2,966.
- The cancer yield was 37% higher in the study group compared to the control group.
- Costs of treating very early- and very late-stage cancer were significantly lower than those of treating intermediate stages.
- The proportion of stage A cancers in the study group was significantly higher than in the control group.
Takeaway
This study shows that finding colorectal cancer early through screening doesn't actually save money on treatment costs.
Methodology
The study compared treatment costs for 360 colorectal cancer patients over 3 years, using hospital records and accounts.
Potential Biases
Potential selection bias due to differences in patient demographics between study and control groups.
Limitations
The study did not include costs of routine follow-up and may not account for all treatment-related costs.
Participant Demographics
Patients included both those detected through screening and those presenting symptomatically.
Statistical Information
P-Value
p<0.001
Confidence Interval
Confidence intervals ?25 to ?69
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website